Previous studies have shown the potential of using bispecific radioligands targeting PSMA and other overexpressed proteins, such as gastrin-releasing peptide receptor (GRPR), to improve tumor targeting and increase the detection sensitivity of prostate cancer imaging [30,31]. The gene discussed is GRPR; the disease is neoplasm.